Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berchuck

Showing results (411-420 of 683) with videos related to

Pageof 69
Sort By:
Journal of Pain and Symptom Management|September 4, 2022
Race, Affordability and Utilization of Supportive Care in Ovarian Cancer PatientsMercy C Anyanwu, Onyinye Ohamadike, Lauren E Wilson, et al.
Cancer|August 6, 2014
Patient preferences in advanced or recurrent ovarian cancerLaura J Havrilesky, Angeles Alvarez Secord, Jessie A Ehrisman, et al.
Clinical Genitourinary Cancer|February 11, 2024
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate CancerDaniel Boiarsky, Doga C Gulhan, Hunter Savignano, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 16, 2005
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancerA Alvarez Secord, E L Jones, C A Hahn, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 19, 2013
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying henGustavo C Rodriguez, H John Barnes, Kenneth E Anderson, et al.
JNCI Cancer Spectrum|February 16, 2023
Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD studyMary Katherine Montes de Oca, Quan Chen, Elizabeth Howell, et al.
Communications Biology|June 2, 2022
Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancersBen Horst, Shrikant Pradhan, Roohi Chaudhary, et al.
Research Square|September 18, 2025
Vaginal Microbiome Composition, Diversity and Dysbiosis: The ORCHiD StudyApril Deveaux, Oyomoare Osazuwa-Peters, Yeon Ji Kim, et al.
Frontiers in Oncology|July 8, 2014
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell LinesBrittany Anne Davidson, Jennifer M Rubatt, David L Corcoran, et al.
Pageof 69

Showing results (411-420 of 683) with videos related to

Sort By:
Pageof 69
Journal of Pain and Symptom Management|September 4, 2022
Race, Affordability and Utilization of Supportive Care in Ovarian Cancer PatientsMercy C Anyanwu, Onyinye Ohamadike, Lauren E Wilson, et al.
Cancer|August 6, 2014
Patient preferences in advanced or recurrent ovarian cancerLaura J Havrilesky, Angeles Alvarez Secord, Jessie A Ehrisman, et al.
Clinical Genitourinary Cancer|February 11, 2024
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate CancerDaniel Boiarsky, Doga C Gulhan, Hunter Savignano, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 16, 2005
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancerA Alvarez Secord, E L Jones, C A Hahn, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 19, 2013
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying henGustavo C Rodriguez, H John Barnes, Kenneth E Anderson, et al.
JNCI Cancer Spectrum|February 16, 2023
Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD studyMary Katherine Montes de Oca, Quan Chen, Elizabeth Howell, et al.
Communications Biology|June 2, 2022
Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancersBen Horst, Shrikant Pradhan, Roohi Chaudhary, et al.
Research Square|September 18, 2025
Vaginal Microbiome Composition, Diversity and Dysbiosis: The ORCHiD StudyApril Deveaux, Oyomoare Osazuwa-Peters, Yeon Ji Kim, et al.
Frontiers in Oncology|July 8, 2014
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell LinesBrittany Anne Davidson, Jennifer M Rubatt, David L Corcoran, et al.
Pageof 69